|Bid||13.75 x 900|
|Ask||13.95 x 4000|
|Day's range||13.35 - 14.00|
|52-week range||8.37 - 18.48|
|Beta (5Y monthly)||2.48|
|PE ratio (TTM)||N/A|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||20.33|
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) were skyrocketing 40.2% higher this week as of the market close on Thursday, according to on data from S&P Global Market Intelligence. BioCryst announced preliminary net revenue for hereditary angioedema (HAE) drug Orladeyo of $45.6 million for the fourth quarter of 2021. In addition, BioCryst stated that it has begun enrolling patients in two pivotal clinical studies evaluating its experimental oral Factor D inhibitor, BCX990, in treating rare genetic disease paroxysmal nocturnal hemoglobinuria (PNH).
BioCryst's (BCRX) sole marketable drug, Orladeyo reports preliminary sales for the fourth quarter. The company also provides its revenue guidance for 2022.
BioCryst (BCRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.